DBV's peanut patch posts adherence and severity data, but commercial picture stays incomplete

DBV Technologies has put more evidence behind its VIASKIN Peanut Patch, a skin-applied treatment for peanut allergy in children aged 4 to 7. On 12 November 2026 the company presented fresh analyses from the Phase 3 VITESSE study at the ACAAI meeting in Phoenix. The data add support for the product, but they do not yet answer the questions that determine its commercial value.

The study enrolled 654 children. By month 12, the company says, children on the patch had less severe reactions during supervised food challenges than those given placebo. The summary available to us gives no figures for that severity comparison, so its size cannot be judged.

The clearest new number is adherence. Participants wore the patch as directed 96.1% of the time on average. DBV also reported shifts in immune markers in the direction expected of allergen immunotherapy. Both findings sit alongside the headline result announced earlier, in which 46.6% of children on the patch met the trial's responder threshold, against 14.8% on placebo.

Several items that would shape a commercial case are missing from the information we have. They include how a responder was defined, the safety and tolerability profile, and any plans for regulatory submission. Nor is there anything on pricing, manufacturing capacity or launch timing. Without these, the new data are best read as reinforcing the efficacy story rather than settling the business case.